FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Clinical trials for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) explained in plain language.
Never miss a new study
Get alerted when new FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) trials appear
Sign up with your email to follow new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Race to halt 'Second Skeleton' disease in children and adults
Disease control Recruiting nowThis study is testing an experimental drug called INCB000928 for people with fibrodysplasia ossificans progressiva (FOP), a rare and devastating disease that causes muscles and soft tissues to turn into bone. About 98 participants, including children as young as 2, will receive e…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Hope for halting rogue bone growth in rare disease
Disease control Recruiting nowThis study is observing whether existing anti-inflammatory drugs (anakinra or canakinumab) can help control severe FOP, a rare genetic disorder that causes muscle and soft tissues to turn into bone. Researchers will follow 11 patients, aged 6-30, who have very frequent painful fl…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC